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Abstract
Novel Mechanisms of Antigen processing that enhance BCG vaccine efficacy
Publication No-----------------Christopher Raman Singh. B.A., M.S.
Supervisory Professor: Chinnaswamy Jagannath. Ph.D.
Mycobacterium tuberculosis, the causative agent of tuberculosis, is the most lethal single
infectious agent afflicting man today causing 2 million deaths per year. The World Health
Organization recommends a vaccine as the best option to prevent this disease. The current
vaccine, BCG, has a variable efficacy and does not protect adults. It is known that BCG
vaccine becomes sequestered in special phagosome compartments of macrophages that do
not fuse with lysosomes. Since lysosome fusion is necessary for peptide production and T
cell priming leading to protective TH1 immunity, we hypothesized that vaccine efficacy is
reduced and occurs perhaps due to non-lysosome dependent mechanisms. We therefore
proposed an in depth analysis of phagosome environment, and its proteome to unravel
mechanisms of antigen processing and presentation. We initially discovered that three
mechanisms of pH regulation including vacuolar proton ATPase, phagocyte oxidase and
superoxide dismutase (SOD) secretion from BCG vaccine affect antigen processing within
phagosomes. These studies led to the discovery that a mutant of BCG vaccine which lacked
SOD was a better vaccine. Subsequently, the proteomic analysis of vaccine phagosomes led
to the discovery of novel protease (γ-secretase) enriched on BCG vaccine phagosomes. We
then demonstrated that these proteases generated a peptide from the BCG vaccine which was
presented through the MHC-II pathway to T cells and induced a TH1 response. The
specificity of antigen production from γ-secretase was confirmed through siRNA
knockdown of the components of the protease namely, nicastrin, presenilin and APH, which
led to a decrease in antigen presentation. We therefore conclude that, even though BCG
phagosomes are sequestered and do not fuse with lysosomes to generate peptide antigens,
there are complex and novel in situ mechanisms within phagosomes that are capable of
generating an immune response. We conclude that TH1 immunity to BCG vaccine arises
mostly due to non-lysosome dependent immune mechanisms of macrophages and dendritic
cells.
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CHAPTER 1

INTRODUCTION
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Tuberculosis
Tuberculosis (Tb) is the leading cause of death in man due to a single infectious agent and is
also the number one killer of people co-infected with Human Immunodeficiency Virus
(HIV-1)(1-3). The infection can occur in multiple organs but the most common location of
infection is in the lungs, resulting in pulmonary tuberculosis(4-6). Tuberculosis symptoms
include chronic cough, blood in the sputum, fever and weight loss (6). Tuberculosis is
spread when an infected individual with an active form of the disease coughs. Aerosolizing
the bacteria and spreading it in the air, and droplets are summarily inhaled by other
individuals(6). The majority of people infected are quickly able to contain the infection
within granulomas in lungs. However, approximately five percent of patients develop acute
tuberculosis(6). In many individuals, the infection remains in a latent state until the
individual becomes immune-compromised, and the infection can take advantage of the
person’s compromised state. New threats continue to emerge with this disease, including
the rise of multi-drug resistant (MDR) infections as well as extensively drug resistant (XDR)
infections(7-9).

Mycobacterium tuberculosis
Mycobacterium tuberculosis (M.tuberculosis; Mtb) is the causative agent for tuberculosis.
The genus Mycobacterium was first observed in 1896 by Lehmann and Neumann(10).
Mycobacterial members are bacillary shaped organisms. Mycobacteria are approximately
3µm long, gram-positive and stain acid fast. There are three major groups of antigens
expressed by mycobacteria, cytoplasmic soluble antigens, secreted antigens and cell-wall
lipid-bound insoluble antigens(10), mycobacteria contain large amounts of surface and
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soluble lipids and proteins. Mycobacteria are responsible for two of the most serious
diseases that plague man, tuberculosis and leprosy (Hansen’s disease). Mycobacterium
tuberculosis was first observed and named by Robert Koch in 1882. Currently,
approximately one-third of the world’s population is latently infected with M.tuberculosis,
with a new infection occurring about every second.

TREATMENT AND VACCINATION
There are several options for treatment of tuberculosis, which include the use of first line
drugs such as rifampin, pyrazinamide and isoniazid(11-13). While these drugs are
bactericidal and can treat the infection, they also cause severe liver toxicity in patients.
They are less effective in treatment of MDR or XDR strains of infections, leading to the
alternate use of secondary drugs. To prevent individuals from contracting tuberculosis, a
vaccine Bacille Calmette Guerin (BCG) is used, which is derived from Mycobacterium
bovis. BCG, is a live attenuated vaccine that has been in use since 1921(14-19). It is one of
the safest and most distributed vaccines available, with over one billion doses administered
to date. There are over thirteen different strains of BCG available for vaccination, although
efficacy of the vaccination varies from zero to eighty percent, with a higher efficacy for
protection against childhood pulmonary tuberculosis, but lower efficacy against adult onset
tuberculosis. This lack of long term immunity is likely due to the fact that BCG undergoes
phagosome maturation arrest that prevents the induction of strong, robust and sustained
immune response(14-19). The World Health Organization (WHO) has determined that the
best and most cost effective way to quell this disease is with a novel more effective vaccine.
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DENDRITIC CELLS AND MACROPHAGES
Dendritic cells and macrophages are the major antigen presenting cells of the immune
system. They phagocytose invading organisms, break them down and load peptide
fragments onto either MHC class II for presentation to CD4+ T cells, or MHC class I for
presentation to CD8+ T cells(20). These are important steps in clearing infection since T
cells are capable of feed-back activation of macrophages and DCs through cytokines,
enhance oxidant responses, kill pathogens, help their degradation and enhance immune
responses, through amplifying peptide production (21,22). A simple difference between
macrophages and DCs is that the latter are capable of priming naïve T cells, a process
whereby a T cell that has never contacted an antigen will become ‘sensitized’ and acquire
the ability to respond to a repeat dose of antigen, when exposed to the same antigen (23-26).
Such T cells can also mature into memory T cells when infection is controlled, and then
undergo recall expansion upon re-infection. Macrophages are generally not capable of
priming naïve T cells although they can induce expansion of pre-sensitized T cells. Thus,
DCs are required for the initial priming phase of infection and macrophages for maintenance
of T cell memory. However, this line is blurred since DCs can continuously sample fresh
antigens during infection and expand the ‘repertoire’ of T cells. Thus, effective vaccination
efforts lead to expansion of the activity of both DCs and macrophages.

GENERATION OF AN IMMUNE RESPONSE
As soon as DCs and macrophages (antigen presenting cells; APCs) phagocytose either Mtb
or BCG vaccine, they are enclosed in a lumen called as the phagosome, which is an
invagination of the plasma membrane enclosing the bacterium. The mycobacteria are then
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usually degraded by the acidification, proteolysis and peptides are produced to be presented
on the surface of the APCs. The change that occurs in phagosome over the course of
infection is called ‘maturation’ that generally results in fusion with lysosomes. The peptides
are then recognized by T cell receptor bearing CD4 and CD8 T cells. This generates an
immune response. These events are summarized below.

PHAGOSOME MATURATION
The immune response to bacterial invasion involves phagosome maturation, and fusion with
the lysosome(27). Typically, a bacterium is endocytosed through receptor mediated uptake,
and then resides within an endosomal, membrane bound, compartment, also termed a
phagosome. The phagosome then matures by a process of protein turnover, which
eventually creates a hostile environment within the phagosome, with a low pH and high
proteolytic activity, especially when fused to the lysosome, an organelle containing digestive
enzymes(28). The low pH is usually due to vATPase. After fusion with the lysosome, the
bacteria are killed by one of the several mechanisms including, but not limited to, phagocyte
oxidase, nitric oxide or proteolytic enzymes. Degraded peptides are exported to multivesicular bodies called MIIC compartments where they are assembled into the major
histocompatibility complex (MHC) class II for transport to the cell surface and presentation
to T cells (27). There is a biochemical basis for the ability of Mtb and BCG to cause
phagosome maturation arrest and these events are illustrated in figure-2.

Initially, the phagosome is enclosed in rab5 positive early phagosomes. Rab5 is a Ras
associated protein, which is a Gtpase. The phagosome then acquires additional proteins
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mainly through the generation of PtdIns3P (PI3-phosphate) through the enzymatic action of
phosphatidylinositol 3-kinase hVPS34.
Biochemical basis for maturation arrest of BCG phagosomes

Figure-1: M. tuberculosis and BCG vaccine

Mycobacterium

APC Plasma membrane

persist in infected macrophages by blocking
Phagosome

Rab conversion and affecting Rab effectors.

GTP GDP
Rab 5
Early endosome

Type III phosphatidylinositol 3-kinase
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thus arrest phagosomal maturation (29,30).

THE VACUOLAR PROTON ATPASE
The major mechanism that acidifies the phagosomal environment is the vATPase(31).
Acidification is important for the activation of
H+

some enzymes that are required for the killing

vATPase
H+

and breakdown of Mtb. The other pumps that

pH

Antigen
Presentation

can influence lumen pH are Na+/H+ dependent
proton pump and chloride channel (32,33).
vATPase is a multi-subunit protein that

vATPase

pH

Antigen
Presentation

H+

assembles on the phagosomal membrane and
Bafilomycin
+

pumps Hydrogen (H ) ions into the
phagosomal lumen, thereby acidifying the
lumen (Figure 2). Acidification can be
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Figure 2: Effect of vacuolar proton ATPase
(vATPase) on the regulation of pH inside
phagosomes and the effect of bafilomycin on
vATPase

prevented by the addition of Bafilomycin, which specifically inhibits the action of vATPase
by preventing the assembly of the V0 and V1 components on the phagosomal
membrane(34,35). Bafilomycin therefore prevents acidification of phagosome lumen and we
demonstrated in an earlier report that it neutralizes acidification of the phagosomes
containing Mtb H37Ra within macrophages (36).

TB MATURATION ARREST
One major difficulty with controlling M.tuberculosis infection and enhancing vaccine
efficacy through the use of BCG is that both strains are able to stall the maturation and
fusion with lysosome (37-39). Both BCG and Mtb secrete a phosphatase sapM that
dephosphorylates the PI3-phosphate on the phagosome membrane (40-42). In addition, both
produce several metabolic analogs that compete with host enzymes during the initial events
of PI3-phosphate synthesis. Thus, phagosome maturation inhibition allows the virulent Mtb
to survive and persist within human hosts. On the other hand, BCG vaccination is unable to
induce a protective immune response against Tb because it is not processed by lysosomes
(43-46) (47). In the absence of lysosomal fusion, the mycobacterial phagosomes have been
found to cleave and produce peptides in situ, which is a novel emerging mechanism (48).
This is the focus of our proposal.
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ANTIGEN PRESENTATION
Once an invading pathogen is degraded in the lysosomes, antigens aree loaded onto MHC-II
molecules and shuttled to the cell surface to be presented to T cells. T cells, in turn secrete
cytokines IFNγ, IL-22 and others that act upon macrophages and DCs to enhance their
function. This feedback activation of TH1 immune response is essentiall for the control of
intracellular infectionss with Mtb and BCG vaccine (49-53). Evidence in animal models and
an
human infection strongly indicate that it is the CD4+ IFN-γ+ T cell dependent TH1

Figure-3: Simplified model of antigen processing and presentation
presentation.. BCG vaccine is taken up
into phagosome which fuses with lysosomes. Lysosomes degrade BCG vaccine and peptides
are produced, which are loaded into MHC
MHC-II
II for presentation on cell surface to CD4 T cells.

response that is critical for protection against tuberculosis, although CD8+ T cells also play a
role particularly against long term infection (54,55). Thus, humans depleted of CD4+ T cells
through HIV-11 infection, rapidly succumb to tuberculosis. It is possible that in humans,
humans
CD8+ T cells maintain immune surveillance and amplify both CD8+ and CD8+ T cells when
infection recurs.
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TH1 IMMUNE RESPONSE
The immune system can respond to infection in multiple ways. An innate immune response
provides a short lived immune response(56). However, for long lasting protection, a cell
mediated, adaptive immune response is necessary(57). This response can provide protection
against specific bacteria and infection and can be classified into two types, TH1 and TH2(57).
A TH1 response activates antigen presenting cells such as macrophages and dendritic cells,
and also stimulates B cells to produce opsonizing antibodies, while TH2 responses lead to
mostly immunoglobulin responses. It is believed that a strong TH1 response is needed to
contain and eliminate Mycobacterium tuberculosis(49-53,58). Tuberculosis infection is
characterized by a reduced TH1 response, but sometimes correlates with increased TH2
response in humans living in tropical regions. Induction of a strong TH1 response controlled
by T cells is essential for providing protection against infection by Mtb, and this protection
is initially induced by Mtb infected dendritic cells. When vaccination is used to induce
immunity, DCs are involved. Dendritic cells, while capable of priming T cells may also get,
infected with mycobacteria and show decreased maturation and activation (59-61). Such an
inhibition helps M. tuberculosis to survive within dendritic cells reducing immune
responses, similar to the down-regulation of immune responses within macrophages. Thus,
both Mtb and BCG persist in host macrophages and DCs for years in a latent state.

STATEMENT OF HYPOTHESIS
The BCG vaccine phagosome is arrested at an immature phagosome stage, although it
contains multiple protein components required for antigen processing assembly (48,62-64).
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Thus, phagosomes appear to be peptide processing organelles (65). However, our previous
observations showed that the pH of the phagosome is near neutral, suggesting weak
proteolysis (36). We therefore hypothesize that the efficacy of antigen processing in
phagosomes may be dependent on pH regulating factors, although pH-independent,
membrane associated processes may also be present. Thus, our aims are as follows.
Aim I: Characterize the BCG phagosome for pH regulating processes that determine
efficacy of antigen production.
o Sub Aim IA: Characterize proton pumps that acidify the phagosome lumen
o Sub Aim IB: Investigate if the phagocyte oxidase that regulates oxidants
within phagosomes affects pH of the phagosome and thereby modulates
antigen production
o Sub Aim IC: Determine if phagosome pH can be modulated through the use
of genetic mutants of BCG vaccine

Aim II: Utilize proteomics to identify novel mechanisms that may mediate antigen
processing of the BCG vaccine
o Sub Aim IIA: Characterize the proteomics of BCG vaccine phagosomes
o Sub Aim IIB: Investigate the proteomes of BCG phagosomes from
macrophages & DCs
o Sub Aim IIC: Investigate function of novel target proteins associated with
BCG phagosomes
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CHAPTER 2

Characterize the BCG phagosome for pH regulating processes that determine
the efficacy of antigen production
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CHAPTER 2-1

Characterize the BCG phagosome for pH regulating processes that determine
the efficacy of antigen production

Sub Aim IA: Characterize effects of proton pumps that acidify the phagosome
lumen
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INTRODUCTION

Tuberculosis is the leading cause of death in mankind due to a single infectious agent. The
causative organism, Mycobacterium tuberculosis (M.tuberculosis) is able to parasitize
macrophages of man and animals and grow within them. Paradoxically, macrophages are
also the cells that are capable of killing these organisms through acidification of bacterial
phagosomes, oxidative processes and lysosomal degradation (66-69). M.tuberculosis has
clearly evolved various mechanisms to neutralize these antimicrobial mechanisms. First,
mycobacteria exclude vacuolar proton ATPase (vATPase) a major mechanism of phagosome
acidification(36). Second, mycobacteria elaborate scavenging lipids, catalase-peroxidase and
superoxide dismutases (SOD) to neutralize oxidants (70,71). Third, their phagosomes fail to
fuse with lysosomes (72-74). The BCG vaccine used to prevent tuberculosis produces
antigens largely similar to M.tuberculosis, having been derived from M.bovis, the pathogen
that causes bovine tuberculosis. Interestingly, it seems to have inherited many immune
evasion features of M.tuberculosis that enable it to sequester in immature phagosomes of
macrophages.

We investigated how immunogenic peptides are produced in macrophages and DCs. It was
known that, mycobacterial phagosomes could assemble MHC-II complexes that contained
an epitope of immuno-dominant antigen-85B (Ag85B) which was then presented to the T
cell hybridoma (BB7 T cells), resulting in IL-2 secretion (48). This in vitro model facilitated
investigating mycobacterial antigen processing in APCs but, the molecular mechanisms
remained unclear. We then demonstrated that mouse macrophages infected with BCG
vaccine presented Ag85B epitope to T cells, but the efficacy of presentation was reduced
compared to macrophages infected with Mycobacterium tuberculosis H37Ra, an attenuated
13

mutant of Mtb H37Rv wild type (36). Additional studies described the key finding that a
protease, Cathepsin-D, was required to cleave Ag85B and produce an epitope which in turn,
was presented to T cells through the MHC-II pathway (36).. These events are summarized in
figure-4 below. However, ddespite progress
rogress in our understanding of antigen processing at the
phagosome level, significant questions have remained. What are the factors that determine
the functionn of proteases in the phagosome
phagosome? How does the BCG phagosome
gosome maintain its
lumen at a near neutral pH?? Is it possible to modulate the pH of the phagosomes so that
antigen production can be enhanced
enhanced? To address these questions, we developed two major
hypotheses.

Figure-4:: Hypothetical model of the importance of pH during antigen presentation
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OVERALL HYPOTHESIS
From published literature it is known that a) the enzyme vATPase pumps protons into
phagosomes to make it acidic(36), b) the NADPH oxidase (phagocyte oxidase or phox
pump) secretes superoxide (O2*) that can potentially neutralize incoming protons, thereby
increasing the pH (75), and c) BCG vaccine secretes a powerful enzyme, superoxide
dismutase (SOD) that dissociates the superoxide into molecular oxygen and water, in a
process that increases the pH(76). Thus, the intra-phagosomal pH appears to be the result of
at least three converging and regulating factors. Since BCG derived Ag85B can be cleaved
by Cathepsin-D only at an acidic pH, we proposed the initial hypothesis that peptide
production in phagosomes is dependent upon pH regulation. In this chapter, we specifically
asked whether BCG phagosomes have a functional vacuolar proton ATPase pump and
whether it influences antigen processing.

METHODS
C57BL/6 mouse derived macrophages and dendritic cells were purified as per previously
published methods (METHODS 5-1). They were incubated with varying doses of the
vATPase inhibitor, bafilomycin for 4 or 24 hrs and infected with BCG vaccine strain for 4
hours post bafilomycin treatment. Macrophage or DC monolayers were washed and over
laid with BB7 T cells, which release IL-2 when Ag85B epitope is presented from
macrophages or DCs to T cells (METHODS 5-2). pH of the phagosome was rendered acidic
using the calcium ionophore, nigericin. gfpBCG phagosomes are green due to neutral pH
and were made acidic with nigericin. The effect of vATPase on the pH of the gfpBCG
phagosomes was determined using bafilomycin blockade and then labeling the macrophages
15

with lysosensor-yellow-blue dextran (LSY) dye, revealing acidic phagosomes as blue and
greenish yellow as near neutral pH phagosomes (METHODS 5-10). The BCG strain used
for these experiments was BCG Tice (a sub strain of BCG Pasteur) and kindly supplied by
our collaborator, Dr. D. Kernodle from Vanderbilt University. The growth and maintenance
of BCG and cell cultures are described under Methods section.

RESULTS
Figure-5 demonstrates that treatment of macrophages and DCs with bafilomycin prior to
BCG infection leads to a marked dose dependent inhibition of antigen presentation.
Multiple experiments with both macrophages and DCs confirmed the observation (Table I).
IN contrast global reduction of pH of macrophages using nigericin led to a marked increase
in antigen presentation (Figure-6).
In a previous study, we found that acidic pH enhanced the auto-catalytic degradation of 56
kDa immature Cathepsin-D into 30 kDa active enzymatic form (36). Furthermore, BCG
phagosomes (pH 6.5) had reduced levels of active Cat-D while Mtb H37Ra phagosomes that
acidified (pH 5), had increased levels of Cat-D. We also demonstrated by using siRNA
knock-down that Cat-D was directly involved in cleaving Ag85B to produce an epitope that
was presented to BB7 T cells.
In order to further determine if bafilomycin induced increase of pH affected the generation
of active forms of Cathepsin-D, BCG phagosomes were purified on sucrose gradients and
analyzed using western blot for active and inactive forms of Cat-D. Macrophages were
activated with IFNγ as a positive control and in addition, phagosomes containing latex beads
were purified from naïve macrophages as a negative control. Figure 7 demonstrates that
16

purified gfpBCG phagosomes from bafilomycin treated macrophages show reduced levels of
active 30 kDa Cat-D compared to phagosomes from untreated or IFNγ activated
macrophages. Latex beads that mature quickly into lysosomes showed active Cat-D even
without macrophage activation. Finally, the pH of the phagosomes was estimated using the
fluorescent dye LSY that co-localizes with gfpBCG phagosomes yielding a blue color when
the phagosome lumen pH is acidic. Figure 8A and B illustrate that bafilomycin treatment of
macrophages, increases the pH of gfpBCG phagosomes so that the proportion of green BCG
phagosomes was higher. These data together implicate the vATPase as one major
mechanism of acidification of BCG phagosomes in macrophages.
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Figure-5: Bafilomycin, an inhibitor of vacuolar proton ATPase (vATPase) leads to
reduced antigen 85B presentation in macrophages and dendritic cells. Primary murine
macrophage or dendritic cells were plated into 24 well plates, treated with varying doses of
bafilomycin for 24 hours, infected with BCG Tice for 4 hours, washed and then overlaid
with BB7 T cells. IL-2 secreted by T cells into the supernatant was measured using sandwich
ELISA (data from one of 3 similar experiments).
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Table I: Bafilomycin blockade of vacuolar proton ATPase in two types of antigen
presenting cells inhibits Ag85B presentation in vitro. Macrophages and DCs derived from
C57BL/6 mice were tested for the ability to present Ag85B to BB7 T cells and the inhibitory
effects of bafilomycin were measured using levels of IL-2 as a parameter.
Cell Type
Primary Dendritic Cell

Primary Dendritic Cell

Primary Dendritic Cell

Primary Macrophage Cell

Primary Dendritic Cell

Primary Dendritic Cell

Primary Macrophage Cell

Primary Dendritic Cell

Primary Macrophage Cell
Primary Macrophage Cell

19

Bafilomycin pg/ml IL-2 SD
0
206.60 47.68
13 nM
38.84
0.00
26 nM
43.89
5.28
52 nM
63.64
46.25
0
78.35
14.90
13 nM
39.06
2.17
26 nM
51.13
11.79
52 nM
58.81
10.86
0
170.00
9.00
13 nM
52.01
6.21
26 nM
64.30
7.45
52 nM
71.33
5.59
0
6107.84 2166.96
13 nM
5728.86 3007.87
26 nM
3886.22 2799.95
52 nM
3173.99 748.50
0
2605.51 1233.64
13 nM
1005.21 227.92
26 nM
802.35 14.34
52 nM
658.09 186.48
0
2605.51 1233.64
13 nM
1016.48 247.04
26 nM
1281.32 168.94
52 nM
1671.27 379.33
0
7631.95 2372.56
13 nM
6506.43 924.08
26 nM
4480.83 314.19
52 nM
2056.64 78.55
0
2004.37
0.00
13 nM
1042.40 76.50
26 nM
1417.69 14.34
52 nM
1605.90 86.07
0
873.1553 60.657
30 nM
880.9536 138.59
0
115.3724 9.2659
30 nM
112.2388 18.532

n
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

1500

1000

500

N
ig
er
ic
in
µM

10
0

µm
25

1

µM

N
ig
er
ic
in

N
ig
er
ic
in

0

U
nt
re
at
ed

pg/mL IL-2 per 106
Macrophages and T cells ( ±SD)

2000

Macrophages + BCG Tice

Figure-6: Nigericin, a calcium ionophore that reduces organelle pH in macrophages,
enhances antigen presentation in BCG infected macrophages. Primary murine
macrophages were plated into 24 well plates, treated with varying doses of nigericin for 4
hours, infected with BCG Tice for 4 hours, washed and then overlaid with BB7 T cells for
IL-2 assay as in Figure-5 (one of 3 similar experiments shown).
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Figure-7: Bafilomycin treatment of macrophages increases the pH of the phagosome
lumen and prevents activation of Cathepsin
Cathepsin-D. C57BL/6
/6 derived BMA macrophage cell
line was treatedd with either 100 nM bafilomycin for 18 hrs or 50 ng/mL IFNγ as a positive
activator, followed
llowed by infection with BCG for 24 hrs. Control phagosomes were latex beads
from naïve macrophages. Macrophages were washed and BCG or latex bead phagosomes
were purified on sucrose gradients and analyzed using western blot with antibody to
Cathepsin-D.. Data show that 56 kDa Cat-D inactive form is present in BCG that show
enrichment of active 30 kDaa band after IFNγ treatment, but remain inactive in bafilomycin
treated macrophages. As expected
expected, phagosomes containing latex beads contain active forms
of cat-D, even without macrophage activation. One of two separate experiments with similar
results is shown.
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None

Bafilomycin

Figure-8A: Bafilomycin treatment increases the pH of the phagosome lumen and prevents
acidification. The fluorescent dye Lysosensor yellow-blue dextran remains largely green
in gfpBCG phagosomes after bafilomycin treatment. C57BL/6 derived macrophages were
treated with 100 nM bafilomycin (vATPase inhibitor) for 18 hrs followed by 60 min
treatment with nigericin and infection with gfpBCG for 4 hrs. Macrophages were washed,
incubated in fluormount and phagosomes imaged using a Nikon microscope with metaview
software. gfpBCG co-localizing with LSY were scored blue vs. green bacteria and per cent
co-localizing gfpBCG determined in 100 macrophages in 2 separate experiments.
Quantitation is shown in Figure 8B.
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Figure-8B:: Bafilomycin treatment increases the pH of the phagosome lumen and prevents
acidification. gfpBCG phagosomes were imaged using a Nikon microscope with metaview
software. gfpBCG are generally green since BCG associated phagosomes are near neutral.
Prior treatment of macrophages with nigericin makes them acidic, while treatment with
bafilomycin makes them neutral. Number of gfpBCG fluorescing with LSY were scored blue
(acidic) vs. green (neutral) bacteria and per cent green gfpBCG determined in 100
macrophages of triplicate chambers per experiment in 2 separate experiments (p value
determined using t test).Excitation
Excitation 480 nm and emission 530 nm. LSY dextran was from
Invitrogen, Molecular Probes.
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Chapter 2-2

Characterize the BCG phagosome for pH regulating processes that determine
the efficacy of antigen production

Sub Aim IB: Investigate whether the phagocyte oxidase (phox) that secretes
superoxide into phagosomes affects pH of the phagosome and thereby
modulates antigen production

24

INTRODUCTION
There are several mechanisms that APCs can use in order to defend against invading
pathogens. The vATPase induced acidification of macrophages and dendritic cells leads to
the generation of active forms of Cathepsin-D, that by itself can be bactericidal as well as
proteolytic(36). In addition, a multi-component NADPH oxidase complex (phox)
accumulates on phagosome membrane soon after phagocytosis of mycobacteria (77). The
phox complex has many subunits, including the major components p22phox, p47phox , p67phox
and p91phox (78-81). Proper assembly of these subunits on the membrane of the phagosome
leads to the superoxide-radical O2- being pumped into the phagosomes. Superoxide by itself
is bactericidal for a variety of microbes but in the presence or iron and halide ions leads to
the formation of more bactericidal radicals like hydroxyl radical, H2O2 and hypochlorous
acid. Superoxide is the lead oxidative radical produced from phox complex and can alter the
pH of the phagosome through two mechanisms. In one mechanism superoxide combines
with protons pumped in from vATPase, and forms hydrogen peroxide that can neutralize the
pH. In a second mechanism it can also spontaneously dismutate into oxygen and water to
raise the lumen pH. It has been reported that phox can control the pH of DCs and affect
cross-presentation, a major route for MHC-I type antigen presentation (82). However, its
role in the regulation of antigen presentation through MHC-II has remained unclear.
O2
phox

HYPOTHESIS

O2-

pH

Antigen
Presentation

In this chapter, we hypothesized that inhibition of phox activity
using the NADPH oxidase inhibitor, diphenylene-iodonium chloride,
pH

phox

would reduce pH and lead to enhanced antigen presentation.

Antigen
Presentation

O2
DPI
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Figure-9: Proposed action of phox on
the regulation of pH and the likely
effect of DPI

METHODS
C57BL/6 mouse derived macrophages and dendritic cells were purified as per previously
published methods (METHODS 5-1). They were incubated with varying doses of the
phagocyte oxidase inhibitor diphenylene iodonium chloride (DPI) for 24 hours and infected
with BCG vaccine strain for 4 hrs. Monolayers of cells were washed and over laid with BB7
T cells, which release IL-2 when Ag85B epitope is presented from macrophages or DCs to T
cells (METHODS 5-2). IL-2 was quantitated using sandwich ELISA.

RESULTS AND DICSUSSION
Figure-10 illustrates that the inhibition of phox complex using DPI led to a surprising
decrease in antigen presentation by both DCs and macrophages. We had anticipated in our
initial hypothesis that phox secreted superoxide would either neutralize the protons being
pumped in by vATPase or would rapidly dismutate into oxygen and water. Either of these
events would lead to a neutral pH inside phagosome. Thus, inhibition of the phox enzyme
through DPI was expected to reduce the pH of the phagosome and lead to enhanced antigen
presentation through activation of enzymatically active Cathepsin-D. The fact that DPI
treatment of macrophages and DCs reduced antigen presentation suggests that the pH of the
BCG phagosome was not rendered acidic. Although not anticipated, our observation
appears inconsistent with the recent report that inhibition of the phox through DPI does not
significantly affect the phagosomal pH, when latex beads are used to measure the pH of the
phagosomes in macrophages (83). However, we used live BCG as a phagosome in contrast
with inert latex beads in macrophages, and it was possible that the bacterial derived factors
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could change the intracellular pH. We therefore propose that BCG derived superoxide
dismutase (SOD), which dismutates superoxide anion, interacts with other oxidants within
the phagosome, eventually raising the pH, despite ongoing acidification of the lumen
through vATPase. That, the BCG phagosomes are near neutral was consistent with this
hypothesis (36).

We conclude therefore that both vATPase and phox pumps can alter the pH of the
phagosome while BCG secreted SOD enzyme also perhaps plays a significant role in the
modulation of lumen pH.
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Figure-10: Inhibition of phagocyte oxidase in macrophages and DCs with diphenyleneiodonium chloride leads to decreased antigen presentation. Macrophages and DCs were
incubated with varying doses of DPI for 4 hrs followed by infection with BCG for another 4
hrs (MOI 1:1). Washed monolayers were overlaid with BB7 T cells and IL-2 release
measured after 18 hrs (Mean± SD; one of 2 separate experiments with similar data shown;
all values for DPI treatment are significant compared to untreated)
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Chapter 2-3

Characterize the BCG phagosome for pH regulating processes that determine
the efficacy of antigen production

Sub Aim IC: Determine if phagosome pH can be modulated through the use of
SOD mutants of BCG vaccine
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INTRODUCTION
Data shown in chapters 2-1 and 2-2 showed that blockade of vATPase and phox enzymes
led to inhibition of antigen production thereby indicating that pH determines the level of
antigen production. Thus, there are at least two regulatory mechanisms that control the pH
of the phagosome and affect the antigen production. However, these events excluded the
role played by the BCG vaccine itself, sinc
sincee BCG secretes a powerful enzyme superoxide
dismutase (SOD) that dissociates superoxide into oxygen and water. Unde
Underr physiological
circumstances, BCG infected macrophages show minimal amounts of Ag85B being
produced and presented too T cells
cells, which we hyppthesize is because of a neutral pH (36).
We therefore speculated that under natural circumstances of infection of macrophages, BCG
secreted SOD was inactivating superoxide from phox enzyme and vATPase was not
sufficient to acidify the lumen. In this study
study, we examined the role of SOD.

HYPOTHESIS
In this chapter, we hypothesized that BCG
induced SOD may play role in
determining intra-phagosomal
phagosomal pH perhaps
by dissociating superoxide leading to
molecular oxygen and water. We also
speculated that molecular oxygen may
neutralize protons coming from the
vATPase pump, so that the net effect of
SOD is neutralization of the pH of the
30

Figure-11: BCG secretes copious Superoxide
dismutase (SOD) and raises pH which decreases
cathepsin-D
D activation and thereby antigen
production

phagosome lumen. We therefore hypothesized that a BCG vaccine candidate that does not
secrete SOD or is defective in secreting SOD should be unable to modulate pH of the
phagosome and thereby adversely affect antigen production.

SUPEROXIDE DISMUTASE
Mycobacteria contain genes encoding for superoxide dismutase (SOD)(70,71). Superoxide
dismutase is a secreted enzyme that spontaneously dismutates into molecular oxygen and
water (hence the name). SOD is an essential gene in mycobacteria and can only be
suppressed through genetic manipulation strategies. BCG strains lacking the ability to
produce or secrete SOD were formed from a parent BCG-Tice strain (a kind gift of Doug
Kernodle Ph.D., Vanderbilt University). Three mutants from a parent strain of BCG-Tice
were made, BCG∆SODA, BCG∆SecA2 and BCG∆SODASecA2. These strains are
respectively, BCG that has SOD suppressed, BCG that has the secA apparatus disrupted and
BCG that has both SOD suppressed and SecA2 disrupted. SecA is required for secretion of
SOD from mycobacteria, and therefore knocking out this gene leads to a lack of secretion of
SOD from BCG into the lumen of phagosomes. These strains were constructed by inserting
a hygromycin resistance vector (hygR) into the genes encoding SOD or SecA, thereby
inactivating the target gene (70,84,85).

METHODS
Macrophages and DCs were infected with wild type Tice BCG and the mutants and
analyzed for the induction of IL-2 using the standardized antigen presentation system
(METHODS 5-2). Macrophages were also infected with Tice and mutant strains and
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phagosomes of the bacteria purified using sucrose gradients (METHODS 5-7). The
phagosomes were analyzed for the content of Cathepsin-D protease to determine if the
phagosomes were acidic enough to generate active forms of Cathepsin-D (METHODS 5-3
and 5-4). Furthermore, C57BL/6 mice were immunized subcutaneously with BCG and an
SOD-deficient mutant strain, and 2 weeks later, the spleen T cells were analyzed for CD4+ T
cells secreting IFNγ using flow cytometry.

RESULTS AND DISCUSSION
We demonstrated earlier that preventing acidification of the phagosomes through
bafilomycin treatment inhibits antigen production. Paradoxically, inhibition of phagocyte
oxidase activity via DPI also decreased antigen presentation from BCG vaccine infected
macrophages. These data together suggest that pH is a critical determinant of the phagosome
that determines the antigen production. It is obvious that enhancing antigen production will
make a stronger BCG vaccine, but it is difficult to modulate the pH of the macrophage or
phagosome pH through chemical intervention without causing toxicity. In this study, we
used genetically modified mutants of BCG Tice strain BCG∆SODA, BCG∆SecA2 and
BCG∆SODASecA, to infect the macrophages. The hypothesis was that, BCG strains secrete
copious amounts of SOD enzyme which can detoxify the superoxide and enhance
phagosome pH. Mutants that have reduced SOD would be unable to modify pH and would
therefore be more susceptible to antigen processing and presentation.

Figure 13 illustrates that the SOD mutants were indeed processed better by the macrophages
and DCs, which presented Ag85B better, with elevated IL-2 levels. In order to determine if
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Figure-12: Loss of SOD increases
antigen presentation by macrophages
and DCs.

SOD altered the pH of the phagosome and affected proteolysis, the phagosomes of wild type
Tice and mutants were then purified from macrophages and analyzed for the enzyme
Cathepsin-D using western blot. In our previous studies, we demonstrated that Cat-D was
the major protease that produced Ag85B for presentation to BB7 T cells. In this study
(Figure 14), the active form of Cat-D was enriched within the phagosomes of the mutants
BCG∆SODA and BCG∆SecA2 compared to the wild type Tice phagosomes. This implied
that antigen production by macrophages with the latter mutants correlated with the presence
of active Cat-D (30 kDa). Since the generation of
O2

active Cat-D (30 kDa) from immature Cat-D (56
phox

kDa), is a pH dependent process (36), this suggests
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generate better immune responses at the level of
macrophages was also reflected in mice. Mice immunized with SOD mutants were found to
respond with increased numbers of IFNγ positive CD4+ T cells through Elispot analysis
(Figure 15).
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Figure-13:: The superoxide dismutase (SOD) defective mutant strains of BCG Tice sub
strain (BCG∆SODA,
SODA, and BCG
BCG∆SODASecA2) are more effectively processed by
macrophages to result in enhanced Ag85B presentation to T cells in vitro. Macrophages
or DCs from C57BL/6
/6 mice were infected with either wild type Tice or mutant strains at an
equal MOI (1:1), incubated for 4 hrs, washed and overlaid with BB7 T cells for 18 hr. IL-2
was quantitated
ntitated using sandwich ELISA ((one
one of four similar Elisa experiments shown).
s
P
values obtained by using student t test.
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Figure-14: The phagosomes of superoxide dismutase (SOD) defective mutant strains of
BCG Pasteur sub strain Tice, (BCG∆SODA, BCG∆SODASecA2) contain the more mature
form of Cathepsin-D. Macrophages from C57BL/6 mice were infected with either wild type
Tice or mutant strains at an equal MOI (1:1), incubated for 24 hrs, washed and phagosomes
purified using sucrose gradients. Equal amounts of proteins were loaded onto a 10% SDS
gel and blotted. Bands were then analyzed for Cathepsin-D using western blot with antibody
to Cat-D and antibodies to vATPase and iNOS as positive controls. One of two separate
similar experiments is shown.
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BCGdnSODA) is
Figure-15: The SOD defective mutant strain of BCG sub strain Tice (BCG
more immunogenic in mice
mice. C57BL/6 mice were infected with wild type Tice or SOD
6

mutant strain at 10 CFU per subcutaneous dose and on 7 and 14 days after infection,
splenic T cells were assayed for IFNγ secreting CD4+ T cells using flow cytometry. Data
show that the mutant strain induces a stronger IFN
IFNγ+ CD4+ T cell response than wild type
Tice. One of two separate but similar experiments is shown.
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CHAPTER-2
GENERAL DISCUSSION
Role of pH as a regulatory mechanism for antigen production
The phagosomes of BCG vaccine within macrophages and DCs seem to be regulated by
three separate, but overlapping mechanisms that affect the overall pH of the lumen. Two of
these mechanisms are innate mechanisms of the host macrophages, namely vATPase that
assembles as a multimeric enzyme on phagosomes to acidify, and the multimeric phagocyte
oxidase that also assembles on the phagosome, when BCG vaccine invaginates into the
plasma membrane forming the phagosome. While vATPase acidifies, phox enzyme
alkalinizes the lumen and thus the net pH of the lumen appears to be determined by the
bacterially derived enzyme SOD. SOD has been thought to be an immune-evasive factor
secreted by BCG vaccine that detoxifies the superoxide and in doing so causes the pH to
again become neutral. It is noted here that there are many other pumps that can affect the
phagosome pH and this is a simplified scenario of the complex environment. Blockade of
phox utilizing DPI was able to markedly inhibit antigen presentation, and it is possible that
there are other factors at play. For example, investigators argue that oxidants inactivate
cathepsins (86) Nevertheless, disruption of the SOD enzyme in the BCG vaccine led to an
enhanced immunogenic phenotype of BCG vaccine. This argues that the lumen pH may well
be regulated by vATPase and phox but bacteria like BCG also seem to have evolved to
cause immune evasion through SOD. BCG is therefore able to overcome the effects of
vATPase and phox. Together, these data support our contention that an enhanced
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understanding of the pH regulatory mechanisms of the phagosomes will enable us to design
better vaccination strategies for tuberculosis.
Figure-16: Mechanisms of pH regulation in phagosomes affect antigen production in
macrophages and dendritic cells.
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CHAPTER 3

Aim II
Utilize proteomics to identify novel mechanisms that may mediate antigen
processing of the BCG vaccine
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CHAPTER 3-1

Utilize proteomics to identify novel mechanisms that may mediate antigen
processing of the BCG vaccine

Sub Aim IIA: Characterize the proteins of BCG vaccine phagosomes through
proteomics
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INTRODUCTION
When latex beads or bacteria are internalized into macrophages they are enclosed within a
membrane bound compartment called the phagosome(52,53). Desjardin group did a
comprehensive analysis for the proteins associated with the latex bead phagosome, and
found numerous proteins associated with
the phagosome, many with undefined
functions (87,88). Since particles
phagocytosed by macrophages and DCs are
destined for degradation in lysosomes, the
phagosomes move through successive
stages to lysosome in a process called
maturation or phagosome-lysosome fusion.
This process is regulated in turn by a series
of proteins like rabs and SNARES (89-91).

Compared to the phagosomes containing
latex beads, the bacterial phagosome is

Figure-17: Virtual phagosome demonstrating numerous
proteins on phagosome surfaces.
http://www.dsv.cea.fr/thema/lcp/phagosome/phago2_fr.
htm

more complex because host interaction with bacteria recruits more proteins into the
phagosome. While the phagosome can potentially contain hundreds of proteins, identifying
all the proteins associated with the bacterial phagosome and differentiating them on the basis
of host and bacterial origin is cumbersome using traditional techniques such as western
blotting. Our collaborator, Dr. Qing Bo Li – University of Illinois at Chicago, developed an
innovative process of peptide mapping using proteomics. In this process phagosomes
41

purified from macrophages are subjected to two dimensional gel electrophoresis and spots
are excised and subjected to Mass spectrophotometry analysis. Proteins are identified on the
basis of their amino acid sequence and quantities compared using a software program. These
methods have been published (92-94).

HYPOTHESIS
Since we found that BCG vaccine phagosomes had a near neutral pH and three mechanisms
regulated the internal pH, we hypothesized that perhaps the phagosome also contains
additional proteases that mediate generation of peptides leading to generation of immune
responses.

METHODS
We previously published methods to purify mycobacterial phagosomes from mouse
macrophage cell lines (36). In this study, we infected the C57Bl/6 mouse derived BMA.A1
macrophage like cell line with BCG vaccine and wild type Mtb H37Rv, in addition to
∆fbpA mutant, a novel lysosome-fusion competent vaccine comparable to BCG (95)
(Figure-18). After 24 hrs of infection, the phagosomes were purified using sucrose gradients
and shipped to the laboratory of Dr. Li, UIC, where, a proteomic analysis was performed.
The data were analyzed and presented in a graphical format (additional detailed procedures
are outlined in METHODS 5-9).
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RESULTS AND DISCUSSION
The proteomic analysis found over three-hundred proteins associated with each of the three
species of mycobacterial phagosomes. Statistical analysis was performed to compare the
proteins from purified phagosomes containing one of three mycobacterial strains (BCG,
∆fbpA and wild type H37Rv). We first determined that proteins (e.g., rabs) that are known to
be associated with endosome-phagosome traffic were present in phagosomes. Interestingly,
several proteins of hitherto undefined function were also differentially enriched on the
phagosomes. These are shown as the three distal groups in Figure-19 and the putative
functions of these proteins are reproduced from the literature in Table-I. We observed that
Nicastrin was enriched on Mtb H37Rv phagosomes compared to BCG and ∆fbpA.
However, Nomo, a protein that associates with nicastrin was more enriched on BCG
phagosomes (96-98). Although subtle variations in the quality of phagosomes prepared
could affect the relative amounts of proteins on phagosomes, it was interesting to find that of
the 300 or so proteins on phagosomes, components with protease activity like nicastrin were
enriched. Thus, proteomic analysis identified certain proteins with protease function in
mycobacterial phagosomes. This assumed significance since previous reports indicated that
nicastrin typically associates with two other components, APH and presenilin to form the γsecretase complex. The γ-secretase complex is a membrane-associated protease and
suggested to recycle and remodel phagosomes (99). The data suggested a novel hypothesis,
that nicastrin and associated proteins could play a proteolytic role associated with the
phagosomes.
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Proteomic analysis
•
•
•

BCG vaccine -Pasteur
Wild type M.tuberculosis
H37Rv
ΔfbpA strain-KO strain

Macrophages (BMA cell line
from C57Bl/6 mice) were
infected with H37Rv, ∆fbpA or
BCG-Pasteur
Phagosomes
collected and
purified
Samples frozen
in SDS sample
buffer and
shipped to
UIC, Chicago

BMA cell line: Kovacsovics-Bankowski M, Rock KL.
Science. 1995 Jan 13;267(5195):243-6.

Mass spectroscopy
analysis performed, data
tabulated and statistical
analysis performed

Figure-18: Outline of the procedure used to purify the phagosomes which were then
subjected to proteomic analysis (100)
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Figure-19: Scatter plot of the T2 values of over 300 proteins quantified in the phagosomes
(Φ) of the BCG-, ∆fbpA-, and Mtb H37Rv-infected macrophages. The x,y,z axis represent
the different strains of mycobacteria utilized for this experiment. Each circle represents a
protein, and the size of the circle represents the abundance of the protein on the phagosome
. The color indicates the fold change of the protein over the phagosomes of the other
strains. The marker size is proportional to the square-root of the averaged (5 repeats of
each phagosomal sample) intensity of that protein in the three phagosome samples as
determined by mass spectroscopy (reproduced from Li et al, (92)).
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Table-II: Proteins relatively enriched on BCG phagosomes are noted with putative
function identified from protein data base. There were two studies published, from which
the enriched proteins were identified (92-94,101).

Proteins enriched on BCG phagosome
asparagine synthetase
chaperonin containing TCP1
Cytochrome B5
Nicastrin
Nomo (pM5)
peptidylprolyl isomerase B (cyclophilin B)
Rab 5
Ribosomal Component Proteins

Nicastrin
binding
partner
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Recycling
nutrients

This study Lee et al (134)
+
+
+
+
+
+
+
+
+
+
+

Chaperone for vATPase
PLoS One. 2010 (11):e13930

CHAPTER 3-2

Utilize proteomics to identify novel mechanisms that may mediate antigen
processing of the BCG vaccine

Sub Aim IIB: Compare the proteomics of BCG phagosomes derived from
macrophages and dendritic cells
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INTRODUCTION
While macrophages and dendritic cells are both capable of processing and presenting
peptides to CD4+ and CD8+ T cells, it has been known that only DCs are able to cross-talk
with naïve T cells and prime them for antigen specificity and expansion into effecter T
cells(49,50,52,53). We wondered whether phagosomes of DCs and macrophages are
comparable. Since we identified in our previous chapter that some proteases were enriched
in the mycobacterial phagosomes, we sought to understand whether similar proteins were
present in phagosomes purified from DCs. In this study, we hypothesized that phagosomes
derived from macrophages and DCs were similar in protein content, at least with respect
with some proteases.
METHODS
Methods were similar to those described in the previous chapter but the phagosomes were
fractionated from CY-15, a dendritic cell line provided by Dr. Blankenstein (102). For
comparison, phagosomes of three species of mycobacteria (BCG, wild type H37Rv and
∆fbpA) were purified at the same time from BMA.A1 macrophage cell line. All infections
and incubation conditions were identical, other than the cell line.
RESULTS AND DISCUSSION
DC dericed phagosomes containing BCG, wild type H37Rv and ∆fbpA were analyzed and
found to contain proteins largely similar to those found in macrophages. Table-III & Figure20 illustrate proteins that were commonly found among phagosomes from two cell lines. It
was noted that nicastrin was again found to be enriched on the mycobacterial phagosomes of
DCs.
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Table III: An abridged list of proteins enriched on the phagosomes containing BCG
vaccine, wild type M.tuberculosis (shown as Rv) and ∆fbpA mutant (designated as KO)
analyzed using proteomics. The abundance of nicastrin is highlighted. As in Figure-19 over
350 proteins were analyzed and the numbers indicate the relative expression of proteins
associated with phagosomes containing various strains of mycobacteria and within either
dendritic cells (DCs) or macrophages (MPs).
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Figure-20: Proteins enriched on the phagosomal membranes of mycobacterial
phagosomes (BCG vaccine, M. tuberculosis and ∆fbpA mutant) are illustrated. The
proteins were identified from a more exhaustive list of proteins analyzed on phagosomes of
mycobacteria, illustrated in the Table II. Putative functions are highlighted with arrows.
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CHAPTER 3-3

Utilize proteomics to identify novel mechanisms that may mediate antigen
processing of the BCG vaccine

Sub Aim IIC: Investigate the function of target protein (nicastrin) identified
through proteomics
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INTRODUCTION
Tuberculosis is the leading cause of death due to an infectious disease and BCG is the only
approved vaccine for humans. BCG gives variable protection against tuberculosis depending
upon geographic regions and the variation has been thought to be due to the loss of some
immunogenic antigens, strain variation and population immunity factors. In addition, earlier
studies show that the BCG vaccine sequesters within early endosomes, which do not fuse
with lysosomes (103). Since peptide processing and presentation through MHC-II is
essential, this suggested that antigen presenting cells (APCs) like macrophages and dendritic
cells would be deficient in presenting MHC-II dependent peptides from BCG. Indeed,
phagosomes of BCG were near neutral in pH due to interplay of complex factors involving
vATPase and phagocyte oxidase enzyme and as a consequence, intra-phagosomal cathepsinD was inactive (36). Furthermore, using a T cell hybridoma specific for a major secreted
antigen from BCG antigen 85B, we found that APCs infected with BCG showed a
decreased antigen presentation (36). Curiously, the wild type Mycobacterium tuberculosis
(Mtb) was the first pathogen reported to evade phagosome-lysosome fusion in macrophages
(37-39). It is now evident that BCG vaccine also has immune evasion mechanisms, that
enable the bacterium to be sequestered within non acidic phagosomes (104-106) (Chapter 1).

Tuberculosis is an important disease for which efficient vaccination strategies have been
sought. We therefore initially analyzed alternative mechanisms of antigen processing within
macrophages that facilitate immune recognition of the vaccine or wild type pathogen. We
analyzed the proteome of the phagosomes of BCG as well as the wild type Mtb H37RV,
purified from mouse macrophages (Chapter 3.1, 3.2). We found that nicastrin, a component
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of the enzyme γ-secretase, was enriched on the phagosomes of the wild type Mtb and to a
lesser extent on BCG vaccine phagosomes.

γ-SECRETASE
γ-secretase is a multi-subunit membrane-associated enzyme complex known to participate in
Notch signaling and cleavage of amyloid precursor protein (APP). The complex consists of
nicastrin, presenilin and APH (98,107,108). Previous studies have focused on the role of γsecretase during Alzheimer’s disease; γ-secretase cleaves the Amyloid Precursor Protein
(APP) and the byproduct, amyloid β (Aβ), is the primary component of amyloid plaques that
cause the disease(109,110). γ-secretase cleaves the transmembrane portion of APP,
producing the 4 kDa Aβ peptide, which is implicated in the progression of Alzheimer’s
disease.

Figure-21: Membrane structure of γ-secretase (97)
γ-Secretase has also been implicated during Notch signaling, a critical pathway of cell
development (111,112). Notch signaling involves activation and internalization of Notch
receptors, which bind to ligands. Once internalized, the ligand-receptor complex is
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endocytosed and the complex is cleaved by γ-secretase, releasing a signaling peptide that
translocates to the nucleus for activation of target genes. Finally, a recent study has
demonstrated that γ-secretase is a component of the phagosome, and proposed that it may
remodel the phagosome and recycle its components. In addition, γ-secretase is up-regulated
by IFN-γ while, two additional substrates of γ-secretase, CD-44 and CD-91 are known to be
involved with phagocytosis (112).

HYPOTHESIS
Previous chapters (Chapter 3.1,3.2) demonstrated that nicastrin and Nomo are associated
with mycobacterial phagosomes. Interestingly, BCG vaccine secretes a number or proteins
including Ag85A and B into the phagosome lumen. Since nicastrin associates with APH and
Presenilin to form the γ-secretase complex, which is a membrane associated protease, we
speculated that nicastrin or γ-secretase components can fortuitously cleave BCG vaccine
derived proteins. Thus, we hypothesized that γ-secretase complex may generate immune
responses.

METHODS
C57BL/6 mouse bone marrow derived primary macrophages and DCs were cultured and
infected with BCG (Pasteur) or wild type M. tuberculosis as previously described
(METHODS 5-2). They were overlaid with BB7 T cells specific for Ag85B (kind gift of Dr.
Harding, CWRU) and IL-2 secreted in response to Ag85B was quantitated using ELISA.
siRNA blockade of γ-secretase was carried out using specific siRNAs obtained from Santa
Cruz Biotechnology against nicastrin, APH and presenilin and the control was a scrambled
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siRNA supplied also by the manufacturer. Chemical inhibition of γ-secretase was carried out
using L-685458.

Immunoflourescence analysis for γ-secretase and localization on BCG phagosomes
APCs were infected with gfpBCG or gfpMtb (H37Rv), washed, fixed, counterstained and
scored for immunofluorescence co-localization with antibodies directed against the
components of the γ-secretase as per published procedures (2) (8)(113,114) (METHODS 56).

Membrane or cytosol localization for Nicastrin
Macrophages and DCs were either left naïve or treated with L685458 in 24 well plates,
infected with BCG and washed. Monolayers were washed with PBS, extracted with 0.05%
digitonin, 0.5% sucrose in PBS-EDTA (DSPE) buffer for 15 min to obtain cytosol fraction,
which was then ultra-filtered and stored. The monolayer was washed with cold DSPE three
times and the membrane fraction solubilized with 0.1% tritonX-100 in PBS for 15 min and
stored until western blot analysis.

Mouse experiments
BM derived, CD11c bead purified DCs were infected before or after treatment with
6

L685,458 (1 µg/mL and 10 µg/mL for 4 hrs) with BCG, washed and 10 DCs per mouse
injected i.p. into C57BL/6 mice, using 4 mice per group. Untreated DCs injected into mice
+

+

were negative controls. After 7 days, spleens were removed and IFNγ CD4 T cells were
detected using flow cytometry for intracellular cytokines and by ELIPOST analysis with
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Ag85B re-stimulation (8). All animal procedures were conducted under approved
institutional protocols.

RESULTS AND DISCUSSION
γ-secretase components are enriched on mycobacterial phagosomes: We previously
reported that Nicastrin is enriched on the phagosomes of wild type strain of Mtb (H37Rv)
using Mass-spectrometry analysis of purified phagosomes from mouse macrophages
(Chapters 3-1, 3-2). To determine whether all three γ-secretase components occurred
uniformly on BCG, APCs were infected with gfpBCG and stained for nicastrin, APH and
presenilin using in situ immunofluorescence and followed by analysis of co-localization
patterns. Figure 22 illustrates that all three components of γ-secretase were present and colocalized with gfpBCG phagosomes, although, rather more intense staining was obtained
with nicastrin. Western blot profiles confirmed that the three components of γ-secretase
were present on BCG phagosomes and they could be specifically knocked-down using
siRNA (Figure 23). In addition, BCG phagosomes purified from macrophages using sucrose
gradients had enzymatically active γ-secretase, since they cleaved the amyloid precursor
protein into an 87 kDa product (Figure 24).

Membrane localization of nicastrin: Phagosomes intensely stained with antibody against
nicastrin with very little cytosolic localization (Figure 22). To further confirm its presence
on phagosomes, macrophages were infected with BCG and membrane or cytosol fractions
were performed using digitonin extraction of cytosol and triton-X solubilized, cytosol free
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membranes as described earlier (METHODS 5-11). Nicastrin was exclusively localized to
membrane fraction in the presence or absence of L685,458 (Figure 25)

γ-secretase components process phagosome derived proteins and thus affect antigen
production: Since the proteolytic activity of γ-secretase was known and it was enriched on
inert latex bead phagosomes, it was proposed that it may be involved in recycling and
remodeling phagosome proteins. Interestingly, mycobacteria like BCG vaccine and wild
type Mtb secrete Ag85B that accumulates within the phagosomes (115,116). Ag85B has a
major T cell epitope and is a powerful immunogen for mice and humans. This epitope is
recognized by a T cell hybridoma, which in turn secretes IL-2 upon MHC-II dependent
priming (48,64). We therefore hypothesized that, mycobacterial phagosome derived Ag85B
could be accessed and cleaved by γ-secretase components. Since a specific chemical
inhibitor for γ-secretase (L685,458) is available and has been previously used to block
nicastrin activity, we initially tested the effect of L685,458 on antigen presentation by
macrophages and DCs infected with the BCG vaccine. Figure 26 shows that L685,458 had a
strong inhibitory effect on antigen presentation by both macrophages and DCs. As expected,
a positive control of pepstatin, which is an inhibitor of cathepsin proteases, also inhibited
antigen presentation. Finally, L685,458 showed a dose- dependent effect on antigen
presentation by DCs infected with BCG (Figure 27).

Phagosomes themselves present Ag85B assembled into MHC-II: It has been established
that Mtb phagosomes themselves assemble Ag85B into MHC-II and present to BB7 T cells
(48,64). We speculated that L685,485 may have non-specific effects on antigen
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presentation, including surface expression of MHC-II by macrophages. To rule out such non
specific effects, BCG phagosomes were purified from macrophages using sucrose gradients,
diluted and incubated directly with BB7 T cells. Figure 28 shows that intact BCG
phagosomes treated with L658,485 showed inhibition of antigen presentation from BCG
phagosomes compared to those from untreated and naïve macrophages.

siRNA blockade of γ-secretase affects antigen production in macrophages and DCs:
Nicastrin and presenilin have been reported to possess protease activity on their own (117121). To further define whether the three components of γ-secretase are involved in the
generation of Ag85B peptide epitope through proteolysis, siRNA knockdown experiments
were carried out. APCs were treated or untreated with siRNA against nicastrin, APH and
presenilin followed by BCG or Mtb H37Rv infection and antigen presentation. Table-III
shows the sequences of siRNA probes, which had a mix of at least two or three different
siRNAs, which ensured robust and specific knock-down (Figure 23). Figure 29a (BCG) and
Figure 29b (M.tuberculosis) show that siRNA knock-down of nicastrin , presenilin and
APH components of γ-secretase affected antigen presentation by APCs infected with BCG
and to a significant extent with Mtb. Control scrambled siRNA had no significant effect on
antigen presentation.

L685,458 treatment of DCs affects subsequent in vivo immunogenicity : We have
previously demonstrated that DCs infected with BCG vaccine can be used to elicit immune
responses in mice following vaccination, which are protective against subsequent challenge
with virulent tuberculosis (122). This provided a model to examine the immunogenicity of
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DCs infected with BCG. To obtain further evidence that γ-secretase may play a role during
in vivo immunogenicity, DCs were treated or not with L685458, infected with BCG and
injected to mice. Viability of the DCs was >90% as evaluated by LDH release assays. Two
weeks later, splenic T cells were assayed for Ag85B specific responses of T cells secreting
IFNγ using flow cytometric analysis of T cells harvested from spleens and ELISPOT
analysis for Ag85B reactive T cells. Figure 30 illustrates that, DCs infected with BCG
elicited markedly better IFNγ+ CD4+ T cell response in mouse spleens compared to L685458
treated DCs with BCG. Similarly, ELISPOT analysis of corresponding spleens showed that
they contained a higher proportion of Ag85B specific CD4+ T cells (Figure 30). These data
strongly suggest that γ-secretase is likely to play a significant role in generating a peptide
epitope from phagosome-associated Ag85B, and thus mediate immune recognition of
mycobacteria, that are otherwise sequestered within macrophages and DCs.
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Figure-22: BCG phagosomes within macrophages co-localize with γ-secretase
components. C57BL/6 mice derived primary macrophages were infected with gfpBCG
and stained separately with antibodies to nicastrin, APH, presenilin or isotype control
followed by Texas-red conjugates. Phagosomes co-localizing with γ-secretase components
were scored using laser deconvolution microscopy and plotted. Panels show the three
color panels for nicastrin and merged images for APH and presenilin. Isotype did not stain
phagosomes and gfpBCG in dendritic cells showed a similar pattern (not shown). Bar
graph represents percent co-localizing gfpBCG enumerated in 100 macrophages of
triplicate chambers per experiment (n=3 experiments ± SD).
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Figure-23 (left): siRNA mediated down regulation of phagosome associated
proteins in macrophages and DCs. Macrophages and DCs were treated with siRNA vs.
nicastrin, APH or presenilin and then infected with BCG organisms. After 24 hrs,
phagosomes were purified and tested in western blot against antibodies against the
proteins. Blot profile shows down-regulation of proteins after siRNA treatment.
Figure-24 (right): BCG phagosomes were purified from macrophages on sucrose
gradients and analyzed for ability to cleave the amyloid precursor protein (APP).
Macrophages were washed and infected with BCG. They were mixed for 4 hours and left
overnight. Cells were then scraped and BCG phagosomes isolated using sucrose
gradients. Phagosomes were collected and incubated in PBS containing 5 mm EDTA and
0.5 mm 1, 10-phenanthroline for 2 hours. Supernatants were analyzed using western blot
and the 87 kDa APP band was detected using an antibody to APP (90 kDa marker).
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Figure-25: Nicastrin is a membrane associated protease. Untreated or L685,458
treated macrophages were infected with BCG vaccine strain and 24 hrs later, membrane
and cytosol fractions were purified. After protein determination, equal amounts were
loaded onto SDS-gels, electroblotted and analyzed for nicastrin using an antibody.
Nicastrin is localized only to membrane fractions.

62

Figure-26: APCs infected with BCG vaccine present mycobacterial Antigen-85B to T
cells and the process is inhibited by the γ-secretase inhibitor, L-685458. The
primary APCs from C57BL/6 mouse bone marrow were treated or not with varying doses
of γ-secretase inhibitor L-685485, followed by infection with BCG and antigen
presentation to BB7 T cell hybridoma. L-685485 and positive control, Cathepsin inhibitor
pepstatin, both inhibit antigen presentation.
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Figure-27: L685458 shows a dose-dependent inhibition of antigen presentation in
dendritic cells. Primary DCs from C57BL/6 mouse bone marrow were treated or not
with varying doses of γ-secretase inhibitor L-685485 and Ag85B presentation was
evaluated (one of two similar experiments shown).
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Table IIII: Compilation of experiments performed utilizing L685,458
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Figure-28: Purified BCG-phagosomes from macrophages present mycobacterial
Antigen-85B to T cells and the process is inhibited by the γ-secretase inhibitor, L685,458. The primary APCs from C57BL/6 mouse bone marrow were treated or not
(naïve) with 100 µM of γ-secretase inhibitor L-685,485, followed by purification of BCG
phagosomes which were diluted, and incubated with BB7 T cells (pahosome:T cell ratio).
IL-2 released from T cells was measured. L-685,485 inhibits antigen presentation from
BCG phagosomes to BB7 T cell hybridoma (one of two similar experiments shown).
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Table-V: siRNA sequences of probes and controls used to knock-down the components of γsecretase
Santa Cruz APH siRNA is a pool of 2 different siRNA
duplexes:
• Sense: GGUUUGGCGUUGUCCAUUUtt
• Antisense: AAAUGGACAACGCCAAACCtt
• Sense: CAUCAUUAGUGGUGUAACUtt
• Antisense: AGUUACACCACUAAUGAUGtt
Invitrogen APH siRNA has a sequence of
• Sense: AAAGCGGAACACCUCCUGUAGAAG
Santa Cruz Nicastrin siRNA (m) is a pool of 3 different siRNA
duplexes:
• Sense: CGUAGUGGAGAAAGAAGAAtt
• Antisense: UUCUUCUUUCUCCACUACGtt
• Sense: CAACGGCUUGGCUUAUGAAtt
• Antisense: UUCAUAAGCCAAGCCGUUGtt
• Sense: GUGACCCCUUAUCUGACUAtt
• Antisense: UAGUCAGAUAAGGGGUCACtt
Invitrogen Nicastrin siRNA has a sequence of
• Sense: UAUCAUAGACCAUCCGUGAGCUGCC
Santa Cruz Presenilin siRNA (m) is a pool of 3 different siRNA
duplexes:
• Sense: GAGUGGAGCUAGAGAUAGAtt
• Antisense: UCUAUCUCUAGCUCCACUCtt
• Sense: CCAGAAUGACAGCCAAGAAtt
• Antisense: UUCUUGGCUGUCAUUCUGGtt
• Sense: CUACGUGUCCAACCAAUCAtt
• Antisense: UGAUUGGUUGGACACGUAGtt
Invitrogen Presenilin siRNA has a sequence of
• Sense: UAGAAACGCACAGACUUGAUAGUGG
The sequence of Control siRNA-A is:

• Sense: UUCUCCGAACGUGUCACGUTT
• Antisense: ACGUGACACGUUCGGAGAATT
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Figure-29: siRNA blockade of the components of γ-secretase leads to inhibition of
antigen presentation in APCs. APCs were treated or not with siRNA against γ-secretase
components, followed by infection with either BCG (a: top panel) or Mycobacterium
tuberculosis (b: bottom panel) and antigen presentation. siRNA knock down of presenilin
and nicastrin significantly affects antigen presentation (p values, student t test;
comparison between siRNA control vs. siRNA knock downs).
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Table-VI: Compilation of siRNA knockdown experiments performed
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Figure-30: γ-secretase
secretase inhibitor L
L-685458
685458 inhibits the ability of DCs to prime T
cells in vivo. C57BL/6
/6 mouse bone marrow derived DCs were left u
untreated,
ntreated, treated with
a low (1 µg per 106 DCs) or high dose (10 µg per 106 DCs) of γ-secretase
secretase inhibitor LL
685,458 followed
lowed by infection with BCG. Washed DCs we
were
re then injected i.p. to mice. Two
weeks later, spleen T cells were analyzed for IFN
IFN-γ producing CD4+ T cells (panel a) and
Ag85B specific T cells using ELISPOT (panel b).
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CHAPTER 4

DISCUSSION AND CONCLUSIONS
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Tuberculosis is a leading cause of death due to infections in mankind. A vaccine is most
useful to prevent tuberculosis and BCG vaccine has been used for nearly a century, with
partial success. Development of a more successful vaccine is a priority for WHO and
various health institutions around the world. In this study, we sought to understand the
mechanisms through which antigenic peptides are produced from BCG, which are
eventually sorted and presented to the CD4+ T cells through an MHC-II dependent pathway.
We initiated our research looking into the immune-evasive mechanisms of M.tuberculosis,
which is very closely related to BCG vaccine.

The seminal observation by Armstrong and Hart that wild type M.tuberculosis sequesters in
immature phagosomes of macrophages laid the foundation for the pathogenesis of
tuberculosis (123-125). By localizing in immature endosomes and not fusing with
lysosomes, wild type Mtb is able to avoid the proteases, lipases and nucleases within the
hostile environment of lysosomes. Since lysosomal degradation is the source of peptides that
are then sorted into MIIC compartments for MHC-II loading, it seems obvious that the
virulent Mtb has an immune evasion strategy. Interestingly, even the attenuated BCG
vaccine was reported to be sequestered from human CD4+ T cells, although the molecular
mechanisms remained unclear (126). A series of studies following this observation showed
that enabling BCG or its antigens to leak into cytosol enhanced its immunogenicity, overexpression of antigens within BCG boosted its efficacy and finally, rapamycin inhibition of
the mTOR pathway induces BCG to localize into autophago-lysosomes and increases the
vaccine efficacy (122,127-130). These studies have markedly improved BCG vaccine
through genetic or immunologic manipulation. However, the mechanism through which the
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mammalian immune system recognizes sequestered Mtb pathogen or BCG vaccine within
APCs still remains unclear. Such mechanisms are clearly important to devise effective
immunization strategies against tuberculosis.

A significant mechanism through which immune recognition can occur could be through
processing of antigens secreted from Mtb and BCG. Mtb secretes a number of antigens like
Ag85 complex (A, B and C), ESAT-6, CFP-10 and TB10.4 among others. BCG also
secretes Ag85 complex and TB10.4, but is deficient in ESAT-6 and CFP-10 (131-134).
Since secreted proteins are major immune-dominant antigens in mice and humans, it has
been speculated that under natural conditions of infection or vaccination, the immune system
mostly recognizes secreted protein antigens through either MHC-I or MHC-II pathways
(52,53). This is evident from the overwhelming T cell and antibody responses to secreted
antigens of Mtb and BCG vaccine in animal models and humans.

The MHC-II dependent CD4+ T cells appear to be more active against active infection since,
HIV-1 infected humans with CD4+ T cell depletion rapidly succumb to tuberculosis.
However, MHC-I dependent CD8+ T cells also appear important, although, there seem to be
impediments for proteasome-mediated processing of secreted antigens for CD8+ responses.
Thus, despite secreting Ag85 complex proteins, BCG is a poor inducer of CD8+ responses
and expression of pore-forming listeriolysin toxin was found to enhance CD8+ responses in
mice (135). Antigens 85A-B-C and pstS are major immunogenic proteins of BCG vaccine,
and yet, only a limited number of CD8+ epitopes have been mapped using tetramers in mice.
In contrast, most secreted antigens are well known to trigger CD4+ T cells responses,
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although, the sorting of secreted antigens, located in the cytosol into MHC-II dependent
pathway remains unclear. The processing of secreted antigens of BCG vaccine within
phagosomes was therefore a major focus of this study.

We described recently that intact BCG vaccine and its antigens could be routed to lysosome
like compartments through induction of autophagy in macrophages and DCs (122).
However, Ramachandra et al. described that mycobacterial phagosomes by themselves
could assemble peptides in situ into MHC-II complexes, which are then exported to plasma
membranes for presentation to CD4+ T cells (63,64). In subsequent studies, we used an in
vitro Ag85B antigen presentation assay to identify that Cathepsin-D was a major protease
that cleaved Ag85B to produce a CD4+ T cell epitope (36). Though BCG produced limited
amounts of Ag85B epitope to be presented to BB7 T cells, it was interesting because, the pH
of BCG phagosomes was near neutral, and the purified BCG phagosomes contained reduced
amounts of active 30 kDa Cat-D required to produce Ag85B epitope. Keeping in mind that
in vivo, phagosome environment could be variable, we asked a question, whether Ag85B
epitope production in phagosomes was determined solely by pH dependent activation of
Cat-D and similar enzymes or whether other proteolytic processes were present.

Studies described here show that both vATPase and phagocyte oxidase (phox, NADPH
oxidase) play a major role in the regulation of lumen pH, but the BCG vaccine derived SOD
seems to negate the effects of vATPase and phox by maintaining a neutral pH. Thus,
knocking down the expression of SOD through genetic manipulations led to a more
immunogenic phenotype for BCG vaccine. This vaccine is currently under clinical trials and
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it is a possible candidate to replace BCG wild type vaccine. By investigating the pH
regulation processes therefore, we were able to find a novel molecular basis to improve the
BCG vaccine. Even after blockade of vATPase and phox, we observed that macrophages
still presented antigen to T cells. Thus, we speculated that alternate mechanisms or proteases
may be present within the phagosomes.

In an attempt to further characterize proteases associated with the phagosome, we then
performed a proteomic analysis of BCG and Mtb phagosomes and identified that nicastrin
was enriched on phagosomes (92-94). The enrichment of nicastrin on mycobacterial
phagosomes was initially identified during a proteomics that was confirmed by others
(94,136). Data reported in this study suggest that, nicastrin is associated with a proteolytic
cleavage of Ag85B to produce an immune signal. Our observations using proteomic analysis
are novel and thought provoking in several directions. First, we had documented earlier that
the phagosome pH is near neutral that prevents the generation of sufficient levels of active
proteases within the phagosome lumen (36). Being associated with the phagosome
membrane, nicastrin may not be affected by the intracellular environment of the phagosome
and thus may aid in proteolysis, either at the membrane interface or outside the membrane.
We noted that purified BCG phagosomes themselves were capable of priming BB7 T cells
in vitro and this was affected by L685458, an inhibitor of γ-secretase. The assembly of
nicastrin alone or as a part of γ-secretase on the phagosome membrane may also help to
perform a physiological function involved in endosome recycling, as proposed by Jutras et
al. (99). Nicastrin or γ-Secretase may therefore fortuitously cleave the mycobacterial
proteins helping the immune system to recognize the intraphagosomal mycobacteria. Third,
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γ-secretase may potentially produce shorter peptide fragments, and downstream events may
channel them towards an alternate CD8+ pathway. We therefore propose that γ-secretase and
its components perform an unintended proteolytic function at the phagosome level and this
may benefit the host during infections.

It is tempting to hypothesize that we may be able to exploit the proteolysis function of γsecretase. For example, we can clone and express an immunogenic protein into CD44, a
known substrate of γ-secretase and express it within BCG as a secreted protein. Then, one
can expect γ-secretase to cleave CD44 as well as associated antigen and produce peptides
that could conceivably find their way into antigen presentation. Furthermore, we can use an
SOD mutant to express CD44 that will probably facilitate a lumen with acidic environment,
and aid proteolysis in situ. Future studies can focus on these issues to strengthen the BCG
vaccine.

To conclude, a comprehensive examination of events occurring within the BCG vaccine
phagosomes has helped to unravel some novel mechanisms that seem to determine the
efficacy of the BCG vaccine. Our studies have highlighted that the mycobacterial
phagosomes contain in excess of 400 proteins indicating the complexity of the phagosome
and the daunting task of a functional characterization. Interestingly, this study illustrates the
use of a system biology approach to dissect the function of a phagosome-associated protein.
We anticipate that a similar systems-biology approach will enable analysis of other novel
proteins associated with the phagosomes and help in understanding pathogenesis and
vaccine development.
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Figure-31: Summary of findings from this study. Because the BCG vaccine does not fuse
with lysosomes, much of the antigen-85B derived epitope is produced within the
phagosomes. The phagosomes have two pumps, vTPAse and phagocyte oxidase (phox) that
work in opposing directions, reducing pH and increasing pH, respectively. The acidic pH
facilitates the generation of 30 kDa Cat-D that can cleave and produce Ag85B epitope,
which is then presented to the T cells. The BCG vaccine secretes superoxide dismutase that,
in turn, raises pH of the lumen. This leads to reduced levels of antigen production in a
neutral phagosome. In addition to, the pH regulating pumps, a third membrane associated
protease, γ secretase also seems capable of cleaving Ag85B. Thus, the BCG vaccine
phagosome is a critical determinant of immune responses originating from macrophages and
DCs.
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Chapter 5

Materials and Methods
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5-1 PRIMARY MACROPHAGES, DCS, CEL LINES, AND BCG STRAINS
Bone marrow from C57BL/6 mice (M/F)(4-8 weeks) (Jackson research Labs, USA) was
obtained by flushing both the femur and tibia. The bone marrow pooled from 2 mice at a
time was centrifuged for five minutes at one thousand rotations per minute. The bone
marrows were washed two times in ACK lysing buffer (Fisher BW10-548E), followed by
one milliliter (ml) ,of phosphate buffered saline (PBS), passed through a 36-gauge needle
and suspended in Iscove’s modified Dulbecco’s medium (IMDM) with ten percent fetal
bovine serum (FBS), 20 ng per milliliter granulocyte macrophage colony stimulating factor
(GM-CSF), and antibiotics, penicillin and gentamicin. The cells were then plated into six
well plates and incubated at 37oC, 5% CO2 for one week, while spiking the wells with two
milliliters of fresh media, every two days. After seven days, the wells are flushed and the
cells from several plates are transferred to a 50ml screw cap tube. The cells are pelleted and
resuspended in MACS buffer, PBS containing 0.5% FBS, at a volume of 400µl per 108 cells.
CD11c microbeads (Miltenyi 130-052-001) were then added to the cells, 100µl per 108 cells.
The cells were incubated at 4oC for fifteen minutes, washed once in 1ml of MACS buffer
and resuspended into 500 µl MACS buffer. During this time, the Miltenyi separation
columns (Miltenyi 130-042-201) were prepared by rinsing once with 500 µl MACS buffer,
one column per 108 cells and placed onto magnetic holders. The cells are added to the
columns and the flow through is collected. The macrophages will flow through since they
do not have CD11c on their surface, thereby not binding the microbeads. The columns are
washed three times with 500 µl MACS buffer and then removed from the magnetic holders.
One milliliter dissociation buffer is then plunged through the column, thereby washing the
dendritic cells off the column. Wash off was repeated once. The flow-through macrophages
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were then run through another column repeating the procedure. The cells (DCs and
6

macrophages) are counted and plated into twenty-four well plates with 10 cells per well in
IMDM supplemented with 10% FBS and GM-CSF and allowed to differentiate for 4-7 days.
Medium was replaced with GM-CSF free medium and cells were used for various assays
(36). BMA A1, derived from C57Bl/6 mice, macrophage cell line used for obtaining
phagosomes and was a kind gift from Dr. Kenneth L. Rock (UMASS, Cambridge, USA).

BCG Pasteur was from ATCC collection, BCG Tice strain and the mutants were donated
from Dr. D. Kernodle from Vanderbilt university and gfpBCG was a gift from Dr.
Dhandayuthapani, UTHSC-SA.

5-2 ANTIGEN PRESENTATION ASSAY
Macrophages or dendritic cells in 24 well plates were infected with BCG at a multiplicity of
infection (MOI) of 5:1. The cells were placed on a shaker at 37oC, 5%CO2 for four hours or
18 hrs as per experiment. Monolayers were then washed with fresh medium three times to
remove non-phagocytosed bacteria, and overlaid with 250µl of BB7 T cells, at a ratio of
1:20. These cells specifically recognize MHC class II loaded with a peptide from the
mycobacterial antigen 85B (aa 241-256: VANNTRLWVYCGNGTP). The plates were
either incubated for 4-24 hrs depending upon the experiment. The supernatant was collected
and tested for IL-2 using sandwich ELISA kit from Biolegend Inc (USA) (36).

5-3 PROTEIN ASSAY
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Protein assays for phagosomes were performed utilizing the BCA Protein Assay Kit
(Thermo Scientific Pierce-23225). The protocol followed was as described in the Pierce
BCA Protein Assay Kit. Equal amounts of proteins were loaded per lane of SDS gels in all
experiments.

5-4 WESTERN BLOTS
Western blot analysis was performed utilizing Bio-Rad pre-cast Criterion gels and gel
system. Controls used in all experiments were Pierce Blue Ranger pre-stained markers as
well as the Cruz marker (Santa Cruz Biotechnology, CA). SDS gels were run and
transferred to Bio-Rad Immuno-Blot Polyvinylidene Fluoride (PVDF) membranes. All
primary antibodies were incubated overnight and secondary antibodies for 90 minutes(36).
ECL kit was used to develop the blots.

5-5 ENZYME LINKED IMMUNOSORBANT ASSAY (ELISA)
Following the Biolegend protocol, ninety-six well ELISA plates were coated with 100µl per
well of IL-2 capture antibody (Biolegend 431003 IL-2 Kit) and incubated overnight at 4oC.
The plates were then blocked for two hours with 200 µl PBS containing 1% albumin per
well. After blocking the plates, 100 µl of sample, or IL-2 standard was added and the plates
were then incubated overnight at 4oC. The ELISA plates were washed with PBS containing
0.05% Tween-20 three times. 100µl detection antibody per well was added to each well and
the plates were incubated at room temperature for two hours. The plates were washed again
and 100µl of avidin-HRP per well was added and incubated for thirty minutes. The plates
were washed for the final time and 100µl Sure Blue TMB 1-component per well peroxidase
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substrate (KPL 50-00-01) was added and incubated for fifteen minutes. 50µl Stop solution,
2N H2SO4, was added to each well and the plates were read at 450nm. A standard curve
was calculated using the IL-2 standards loaded on the plates, and the IL-2 content of
samples was determined.

5-6 IMMUNOFLUORESCENT STAINING
Dendritic Cells or macrophages were plated onto 8-chamber glass slides (BD 354118). The
slides were incubated overnight at 37oC, 5%CO2 in activator-free medium or activators, such
as Gm-CSF, for 4 or 24 hrs. Cells were infected with gfpBCG and placed on a shaker at
37oC, 5%CO2 for four hours, removed from the shaker and incubated for 4-8 or eighteen
hours. Slides were washed with PBS three times and 200µl of 2.7% paraformaldehyde was
added to each chamber for fifteen minutes. 200µl of .01mg/ml digitonin in PBS was added
to each well and incubated for eight minutes. The paraformaldehyde was aspirated and cells
were then incubated in 200µl perm buffer, containing 0.1% saponin and 0.05% tween-20 in
PBS, and incubated for thirty minutes. Blocking buffer consisting of 0.1% glycine and 5%
heat inactivated mouse serum in PBS was added and slides were incubated for 30 minutes.
Primary antibody was added to the slides and they were incubated overnight at 4oC. Slides
were then washed thrice with PBS containing 0.05% tween and Texas Red secondary
(Jackson Immunoresearch Chemicals, USA) was added to each well and slides were
incubated for three hours. Isotype specific antibodies were used in the place of primary
antibody as a control in all steps of our experiments. Slides were then washed and rinsed
once with cold methanol. Slides were then scoped and analyzed using a Nikon microscope
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with Metaview software. Co-localization was confirmed using laser confocal microscopy
when needed (36).

5-7 PHAGOSOME FRACTIONATION
The method described by Ullrich et al. to purify mycobacterial phagosomes was used
without modifications [135]. Antigen presenting cells (BMA.A1 cell line, CyDC cell line or
primary cells) were infected at an MOI of 5:1 with BCG, or other mycobacteria, gently
mixed for 4 hours at 37oC, 5% CO2 and then incubated for eighteen hours. Cells were then
scraped and samples were pooled from multiple flasks. Cells were washed three times with
PBS and resuspended in an anti-protease mix consisting of 1 µg/mL leupeptin, 1 µg/mL
pepstatin and 1 mM phenylmethyl sulfonylfluoride. Cells were then transferred to a glass
cell grinder and ground prior to being passed through a syringe with a 27½ gauge needle.
Cells were then layered on a gradient composed of 4 mL 50% sucrose and 2 mL of 12%
sucrose and centrifuged for 90 minutes at 4oC at 2000 rpm. The interface, composed of
phagosomes, was collected after removing the upper 12% sucrose layer (post nuclear
supernatant). The phagosomes were pelleted at 12000 rpm for 5 min and the supernatant
was discarded. 500 µL of PFB (0.5 mm EDTA, 0.5 mM EGTA, 0.05% gelatin and 20 mM
hepes brought to a pH of 7.0) was added and phagosomes were overlaid on 2 ml of 10%
Ficoll 70,000 in 5% sucrose, centrifuged at 2000 rpm for 30 min and the interface was
collected. This second step was repeated once more to yield > 95% pure phagosomes as
judged by electron microscopy (137).

5-8 PROTEOMIC ANALYSIS (method reproduced from Li et al, IJCLM(92,93))
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Phagosomes were fractionated as noted previously, Methods, prior to further analysis.
Samples of 100 µg phagosomes containing BCG, Mtb H37Rv or ∆fbpA were fractionated
into five SDS/PAGE gel fractions. Peptide extracts from each fraction were purified before
analysis. Analysis was performed with a nanoLC/LTQ-FTMS system at the Proteomics and
Informatics Facilities Services in the Research Resources Center at University of Illinois at
Chicago (PISF-RRC-UIC), which is supported by the Searle Funds at the Chicago
Community Trust. Each extract was injected once and a total of 15 LC/MS injections were
performed for the three phagosome samples. With the Sorcerer server (Sage-N Research,
Inc.; Milpitas, CA) hosted at the PISF-RRC-UIC, the raw data files were compared to a
composite database containing the protein databases of mouse, H37Rv, BCG, and their
reversed decoy databases. The raw data files were then converted to mzXML files using the
Trans-Proteomic Pipeline software. The mzXML files were searched against the composite
database as well. For reference, the peptide mass tolerance was set at 15 ppm with
methionine oxidation as a differential modification. Up to 2 missed cleavages and an
isotope check using a mass shift of 1.003 amu were allowed with only MS/MS
identifications with peptide probability above 0.5 for quantitation being accepted for
publication.
5-9 siRNA KNOCKDOWN OF PRIMARY CELLS
A specific approach to inhibit γ secretase component expression is the use of siRNA against
APH, nicastrin or presenilin. This procedure from Santa Cruz Biotechnology involves
transfecting macrophages or dendritic cells with long double stranded RNA, which upon
uptake, enter the RNA interference pathway. The RNA is degraded into 19-21 nucleotide
fragments by an RNAase III enzyme called dicer, and subsequently this binds to the
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complimentary mRNA sequence. The coupled mRNA is then cleaved prior to translation,
thus inhibiting production of the targeted protein. Primary cells are transfected utilizing
Santa Cruz’s Transfection Reagent and incubated for 30 hours. siRNA-transfected as well as
naїve cells were infected with mycobacterial strains for 4 hrs and washed. At this stage,
replicate wells of cells were lysed to determine protein content by western blot. Other wells
were washed and incubated in medium for 24 h and then overlaid with BB7 T cells. IL-2
was then estimated at several time points of incubation. The controls used are scrambled
sequences of siRNA.

5-10 pH DETERMINATION
Macrophages were plated in 8-well coverglass bottom chambers (Lab-Tek, Naperville, IL).
After 24 h when the cells were 30–50% confluent, they were incubated in 1 mg/ml of the pH
indicator LysoSensor Yellow/Blue dextran (Molecular Probes, Eugene, OR) for 12 h and
then washed with cold PBS. Macrophages were acidified using 60 min incubation with
nigericin if needed. LysoSensor is an UV-excited fluorophore with emission maxima at 390,
450 and 530 nm that are proportional to pH. This dextran-conjugated indicator is taken up
by vesicles that are part of the endocytic pathway and are comprised of endosomes and
lysosomes. Higher 530/450 nm ratios correlate with a lower pH. The labeled cells were
observed with a fluorescent microscope (Nikon microscope with a Metamorph image
analysis software), using excitation at 360 nm and an emission filter at 450 nm and a long
pass emission filter at 515 nm. With the dextran-labeled LysoSensor Yellow/Blue dye, the
ratio of 530/450 nm emission was calculated for endocytic vesicles by using the MetaMorph
Image (or Metaview) processing system (Version 4.5r5, Universal Imaging Corp., PA) and
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averaged for each image(138). The 530/450 nm ratio was calculated on a minimum of 100
intracellular phagosomes in each of the four images analyzed per experiment and each
experiment was repeated three times (arbitrarily we can score the phagosomes as green and
blue and express their ratio to reflect the pH).

5-11 FRACTIONATION OF CYTOSOL AND MEMBRANE FRACTIONS FROM
PRIMARY CELLS
Primary macrophages or dendritic cells are plated into 6-well plates at a count of 2x106 cells
per well in IMDM with 10% FBS. The APCs are incubated 24 hours prior to treatment or
infection. If a treatment is performed on the APCs, they are treated for 24 hours prior to
infection, which is then allowed to proceed for an additional 24 hours. The cells were then
washed thrice with 1 ml PBS and then incubated on ice with 300 µl digitonin in a sucrose
buffer(139,140). The plates are incubated for 10 minutes and the buffer is then collected
and pooled. The samples are then concentrated using Centricon centrifugal ultrafiltration
vials until a final volume of 100 µl is obtained. This sample is termed the cytosolic fraction.
The wells of the plates are then scraped using a cell scraper, and rinsed with 1ml PBS
combining wells of the same sample. The samples are then centrifuged at 12000 rpm for
five minutes, and washed three times with PBS containing 10% Triton-X and then
resuspended in PBS. This portion of the sample is now termed the membrane fraction and
stored after protein determination.
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